What Researchers Did
Researchers built a decision model to compare the cost and health outcomes of adding hyperbaric oxygen therapy (HBOT) to standard care versus standard care alone for diabetic foot ulcers in Canada.
What They Found
This Canadian cost-effectiveness modelling review estimated that adding HBOT to standard care for diabetic foot ulcers cost CND$40,695 per patient over 12 years versus CND$49,786 for standard care alone, with 3.64 versus 3.01 quality-adjusted life-years. The model used a 65-year-old cohort and a Ministry of Health perspective. Its efficacy inputs came from studies in a literature review, so the results depend on those studies and on the model's assumptions. Treating all prevalent cases in Canada was estimated at CND$14.4-19.7 million per year over 4 years. If seven-person chambers were used, nineteen to thirty-five more machines would be needed nationally. The authors concluded that adjunctive HBOT is cost-effective compared with standard care and that extra capacity would be needed if it became the standard of care across Canada.
What This Means for Canadian Patients
For people with diabetic foot ulcers, this study suggests that, in its model, adding HBOT to standard care lowered long-term costs and gave more quality-adjusted life-years. It is an economic projection, not a trial of patients, and it does not report individual treatment results. The abstract also says wider use would need more chambers, so access could depend on capacity.
Canadian Relevance
The study was done as part of a Canadian assessment and used Canadian cost and utilization data from government records. The authors modelled costs from a Ministry of Health perspective.
Study Limitations
The findings come from a model that relies on efficacy data taken from other studies and on assumptions about a hypothetical 65-year-old cohort, so real-world costs and outcomes could differ.